查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1975308

全球遗传性血管性水肿治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Hereditary Angioedema Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 133 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计遗传性血管性水肿治疗的市场规模将从 2025 年的 47.3 亿美元增长到 2034 年的 91.8 亿美元，2026 年至 2034 年的复合年增长率为 7.66%。

由于人们对遗传性血管性水肿 (HAE) 的认识不断提高，以及诊断能力的提升，全球 HAE 治疗市场正稳步成长。遗传性血管性水肿是一种罕见的遗传性疾病，需要标靶治疗，而生物製药和血浆衍生疗法的进步已显着改善了患者的治疗效果。此外，病患支援活动的拓展和专科医疗中心就诊管道的改善也促进了市场成长。

市场成长主要受持续的临床研究、新治疗方法的监管核准以及医疗保健支出增加的推动。製药公司正大力投资创新治疗方法，包括单株抗体和基因疗法。此外，已开发国家优惠的健保政策也有助于提高病患获得先进治疗的机会。

随着在研发线产品和精准医疗方法日益受到关注，未来前景乐观。长效和可自行给药治疗方法的开发有望提高患者的用药便利性和依从性。随着全球宣传宣传活动和基因筛检工作的扩展，遗传性血管性水肿治疗市场有望持续稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球遗传性血管性水肿疗法市场：依治疗方法

  • 市场分析、洞察与预测
  • C1酯酶抑制剂
  • 缓激肽B2受体拮抗剂
  • 激肽释放酶抑制剂
  • 其他的

第五章 全球遗传性血管性水肿治疗药物市场：依最终用途划分

  • 市场分析、洞察与预测
  • 预防性治疗
  • 一经请求

第六章 全球遗传性血管性水肿疗法市场：依给药途径划分

  • 市场分析、洞察与预测
  • 静脉注射
  • 皮下注射
  • 口服

第七章 全球遗传性血管性水肿治疗药物市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 亚太其他地区
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • BioCryst Pharmaceuticals Inc
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies Inc
    • KalVista Pharmaceuticals Inc
    • Takeda Pharmaceutical Company Limited
    • Pharming
简介目录
Product Code: VMR112112397

The Hereditary Angioedema Therapeutics Market size is expected to reach USD 9.18 Billion in 2034 from USD 4.73 Billion (2025) growing at a CAGR of 7.66% during 2026-2034.

The Global Hereditary Angioedema Therapeutics Market is experiencing consistent growth due to increasing awareness and improved diagnostic capabilities. Hereditary angioedema (HAE) is a rare genetic disorder requiring targeted treatment approaches, and advancements in biologics and plasma-derived therapies have significantly improved patient outcomes. Growing patient advocacy and better access to specialized care centers are also contributing to market expansion.

Market growth is driven by ongoing clinical research, regulatory approvals for novel therapies, and rising healthcare expenditure. Pharmaceutical companies are investing heavily in innovative treatments, including monoclonal antibodies and gene-based therapies. Additionally, favorable reimbursement policies in developed economies are enhancing patient access to advanced therapeutics.

Future prospects are optimistic as pipeline products and precision medicine approaches gain traction. The development of long-acting and self-administered therapies is expected to improve patient convenience and adherence. As awareness campaigns and genetic screening initiatives expand globally, the hereditary angioedema therapeutics market is likely to achieve sustained and progressive growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

  • C1-Esterase Inhibitor
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

By End-use

  • Prophylaxis
  • On-Demand

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral

COMPANIES PROFILED

  • BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals, CSL, Attune Pharmaceuticals, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited, Pharming
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment
  • 4.2. C1-Esterase Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Bradykinin B2 Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Kallikrein Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End-use
  • 5.2. Prophylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. On-Demand Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Treatment
    • 7.2.2 By End-use
    • 7.2.3 By Route Of Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Treatment
    • 7.3.2 By End-use
    • 7.3.3 By Route Of Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Treatment
    • 7.4.2 By End-use
    • 7.4.3 By Route Of Administration
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Treatment
    • 7.5.2 By End-use
    • 7.5.3 By Route Of Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Treatment
    • 7.6.2 By End-use
    • 7.6.3 By Route Of Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 BioCryst Pharmaceuticals Inc
    • 9.2.2 Ionis Pharmaceuticals
    • 9.2.3 CSL
    • 9.2.4 Attune Pharmaceuticals
    • 9.2.5 Adverum Biotechnologies Inc
    • 9.2.6 KalVista Pharmaceuticals Inc
    • 9.2.7 Takeda Pharmaceutical Company Limited
    • 9.2.8 Pharming